vs
爱尔康（ALC）与博士伦健康（BHC）财务数据对比。点击上方公司名可切换其他公司
博士伦健康的季度营收约是爱尔康的1.1倍（$2.8B vs $2.6B），爱尔康净利率更高（6.8% vs -3.7%，领先10.5%），博士伦健康同比增速更快（9.3% vs 4.0%）
爱尔康是瑞美合资的制药及医疗器械企业，专注于眼健康护理产品领域。公司注册地为瑞士弗里堡州，全球总部设于日内瓦，核心运营基地位于美国得克萨斯州沃思堡，当地员工规模约4500人。
博士伦健康公司（Bausch Health）是一家业务多元化的北美跨国制药企业，全球总部位于加拿大魁北克省拉瓦尔，美国总部设在新泽西州布里奇沃特。公司专注于胃肠病、肝病、神经科、皮肤科、牙科、医疗美容等领域的药物研发、生产及销售，同时提供品牌药和仿制药产品，业务覆盖全球市场。
ALC vs BHC — 直观对比
营收规模更大
BHC
是对方的1.1倍
$2.6B
营收增速更快
BHC
高出5.3%
4.0%
净利率更高
ALC
高出10.5%
-3.7%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.6B | $2.8B |
| 净利润 | $176.0M | $-103.0M |
| 毛利率 | 53.5% | — |
| 营业利润率 | 9.5% | 17.0% |
| 净利率 | 6.8% | -3.7% |
| 营收同比 | 4.0% | 9.3% |
| 净利润同比 | -21.1% | -205.1% |
| 每股收益（稀释后） | $0.35 | $-0.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALCBHC
| Q4 25 | — | $2.8B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | $2.6B | $2.5B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | $2.5B | $2.4B | ||
| Q1 24 | — | $2.2B |
净利润ALCBHC
| Q4 25 | — | $-103.0M | ||
| Q3 25 | — | $179.0M | ||
| Q2 25 | $176.0M | $148.0M | ||
| Q1 25 | — | $-58.0M | ||
| Q4 24 | — | $98.0M | ||
| Q3 24 | — | $-85.0M | ||
| Q2 24 | $223.0M | $10.0M | ||
| Q1 24 | — | $-64.0M |
毛利率ALCBHC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 55.0% | — | ||
| Q1 24 | — | — |
营业利润率ALCBHC
| Q4 25 | — | 17.0% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | 9.5% | 17.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | 21.8% | ||
| Q3 24 | — | 12.7% | ||
| Q2 24 | 12.7% | 16.2% | ||
| Q1 24 | — | 13.1% |
净利率ALCBHC
| Q4 25 | — | -3.7% | ||
| Q3 25 | — | 6.7% | ||
| Q2 25 | 6.8% | 5.8% | ||
| Q1 25 | — | -2.6% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | -3.4% | ||
| Q2 24 | 8.9% | 0.4% | ||
| Q1 24 | — | -3.0% |
每股收益（稀释后）ALCBHC
| Q4 25 | — | $-0.30 | ||
| Q3 25 | — | $0.48 | ||
| Q2 25 | $0.35 | $0.40 | ||
| Q1 25 | — | $-0.16 | ||
| Q4 24 | — | $0.24 | ||
| Q3 24 | — | $-0.23 | ||
| Q2 24 | $0.45 | $0.03 | ||
| Q1 24 | — | $-0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $1.3B |
| 总债务越低越好 | — | $20.8B |
| 股东权益账面价值 | $22.1B | $-554.0M |
| 总资产 | $31.4B | $26.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALCBHC
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $1.4B | $1.7B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $719.0M | ||
| Q2 24 | $1.4B | $595.0M | ||
| Q1 24 | — | $733.0M |
总债务ALCBHC
| Q4 25 | — | $20.8B | ||
| Q3 25 | — | $21.0B | ||
| Q2 25 | — | $21.7B | ||
| Q1 25 | — | $21.5B | ||
| Q4 24 | — | $21.6B | ||
| Q3 24 | — | $21.5B | ||
| Q2 24 | — | $21.7B | ||
| Q1 24 | — | $22.1B |
股东权益ALCBHC
| Q4 25 | — | $-554.0M | ||
| Q3 25 | — | $-565.0M | ||
| Q2 25 | $22.1B | $-764.0M | ||
| Q1 25 | — | $-1.2B | ||
| Q4 24 | — | $-1.3B | ||
| Q3 24 | — | $-1.2B | ||
| Q2 24 | $20.9B | $-1.2B | ||
| Q1 24 | — | $-1.1B |
总资产ALCBHC
| Q4 25 | — | $26.4B | ||
| Q3 25 | — | $26.8B | ||
| Q2 25 | $31.4B | $27.3B | ||
| Q1 25 | — | $26.4B | ||
| Q4 24 | — | $26.5B | ||
| Q3 24 | — | $26.5B | ||
| Q2 24 | $29.7B | $26.5B | ||
| Q1 24 | — | $26.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $495.0M |
| 自由现金流经营现金流 - 资本支出 | — | $403.0M |
| 自由现金流率自由现金流/营收 | — | 14.4% |
| 资本支出强度资本支出/营收 | — | 3.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $1.0B |
8季度趋势，按日历期对齐
经营现金流ALCBHC
| Q4 25 | — | $495.0M | ||
| Q3 25 | — | $405.0M | ||
| Q2 25 | — | $289.0M | ||
| Q1 25 | — | $211.0M | ||
| Q4 24 | — | $601.0M | ||
| Q3 24 | — | $405.0M | ||
| Q2 24 | — | $380.0M | ||
| Q1 24 | — | $211.0M |
自由现金流ALCBHC
| Q4 25 | — | $403.0M | ||
| Q3 25 | — | $314.0M | ||
| Q2 25 | — | $190.0M | ||
| Q1 25 | — | $96.0M | ||
| Q4 24 | — | $495.0M | ||
| Q3 24 | — | $334.0M | ||
| Q2 24 | — | $302.0M | ||
| Q1 24 | — | $129.0M |
自由现金流率ALCBHC
| Q4 25 | — | 14.4% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 4.2% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 13.3% | ||
| Q2 24 | — | 12.6% | ||
| Q1 24 | — | 6.0% |
资本支出强度ALCBHC
| Q4 25 | — | 3.3% | ||
| Q3 25 | — | 3.4% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 4.1% | ||
| Q3 24 | — | 2.8% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 3.8% |
现金转化率ALCBHC
| Q4 25 | — | — | ||
| Q3 25 | — | 2.26× | ||
| Q2 25 | — | 1.95× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.13× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 38.00× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALC
暂无分部数据
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
